Physician profile
Jesse Dabit
NPI 1740643907
$738.88
in general payments reported to CMS, 2019-2025
9 companies · $68.54 in 2025
The $68.54 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $339 · 2024: $198 · 2025: $68.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $149.03 | 2022 | |
| Spr Therapeutics, INC | $133.91 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $114.62 | 2024 | Saphnelo |
| Aurinia Pharma U.S., INC. | $112.59 | 2022 | |
| Pfizer INC. | $83.09 | 2024 | |
| Radius Health, INC. | $77.10 | 2022 | |
| Glaxosmithkline, LLC. | $26.24 | 2025 | Benlysta |
| Amgen INC. | $21.43 | 2025 | Tavneos |
| Sandoz INC. | $20.87 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Dabit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.